Mahamat Djalal

Meeting with elected and non-elected officials to discuss the Association's priority issues. Meetings with elected and non-elected officials to discuss the federal government's dental care program.

Régime canadien de soins dentaires Discussion avec des titulaires de charges publiques concernant le Régime canadien de soins dentaires (RCSD) en lien avec son implantation et ses impacts sur les cliniques dentaires du Québec.

Démarches visant à obtenir un financement pour soutenir et consolider une production pharmaceutique locale et robuste au Canada. Démarches visant à renforcer l'autonomie pharmaceutique au Canada, dans le contexte de la modernisation réglementaire suivant les consultations sur les initiatives visant à réduire le fardeau administratif pour faciliter l’accès aux médicaments.

The CUSMA renegotiation and issues related to the pharmaceutical industry in Canada. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026. Free trade agreements as they relate to biomanufacturing industry in Canada. Engage, as a stakeholder, to provide input into the re-negotiation of the Canada USA Mexico trade agreement "CUSMA" Patented Medicines Regulations modernization as outlined in Budget 2026, that will leverage existing technology, enabling faster and more cost effective procedural processes. Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB) Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines. Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.

Free trade agreements as they relate to biomanufacturing industry in Canada Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB) Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB) Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission. Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines. Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.

Meeting with elected and non-elected officials regarding Pharmacare and Health related issues.

HEALTH DATA INTEROPERBILITY: Provide CMA’s perspective as it relates to health data interoperability that would ensure providers have access to the right information at the right time when providing care, and improve patient outcomes and their health care experience. BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care. HARMFUL ONLINE CONTENT: Advocate to address the escalation of online harassment, intimidation, and threats of violence targeting physicians, other health workers, and anyone seeking health care treatment, including measures to strengthen the Criminal Code of Canada and the Canadian Human Rights Act. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed. HEALTH PROMOTION AND DISEASE PREVENTION: Increased investments in health and social-determinants-of-health related programs, including measures to address the opioid crisis, mental health and addictions, and the regulation of natural health products. ADMINISTRATIVE BURDEN: Advocate for measures to alleviate the administrative burden on physicians and support their professional wellbeing, including investment to facilitate the development of EHRs and EMRs in Canada, improved remuneration for the completion of federal health forms, the development of a Federal Disability Benefit, ensuring that physicians are not captured in the definition of "promoters" in the Disability Tax Credit Promoters Restrictions Regulations, providing clarity and guidance on federal forms, and advocacy on discontinuing the requirement that employees present sick notes to their employers. The CMA is advocating that the trade of medical goods and medications be protected to avoid disruptions to patient care. Specifically, that the government: Continue to ensure pharmaceutical products and medical devices are not included in any countermeasures on tariffs. Improve safeguards for Canadian health data. Improve labour mobility so physicians can work across the country. Make it easier for qualified physicians to immigrate and work in Canada, including by fast-tracking immigration steps for US physicians. PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. INTEGRATED HEALTH HUMAN RESOURCES Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. MEDICAL MIS/DISINFORMATION: Provide CMA’s perspective on the impacts of medical misinformation and disinformation, including on public trust in science, medicine, and public health experts. INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key s

Meetings with elected and non-elected officials to establish the Mira Foundation as the leading reference in services for people with disabilities (visual, motor, and autism spectrum disorders) and to secure sustainable financial support as well as regulatory changes.

Canadian Environment Protection Act, with respect to compliance and enforcement policy. To discuss testing methods, training, and protocols for mineral analysis and the classification of amphibole minerals.

Meetings with elected and non-elected officials regarding the United States tariffs. Meetings with elected and non-elected officials regarding the Publication of the regulatory framework paper and technical paper to advance the plastics circular economy. Meetings with elected and non-elected officials regarding the company’s sustainability, recyclability and environmental policies.

Policies aimed at reinforcing pharmaceutical supply chain. Discussion regarding the launch of new branded product in the rare disease space Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development. Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project. Policies aimed at facilitating generic drug repurposing. Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products. Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.

Policy development activities and outreach to Government of Canada representatives related to the Prince Rupert Port Authority’s current operations, future corporate development and matters impacting the Canadian marine transportation sector. Identifying potential funding opportunities for terminal development under the Government of Canada's forthcoming infrastructure program (previously the Building Canada Plan).